Solid Cancers
Conditions
Keywords
Advanced solid cancers, HER2, EGFR
Brief summary
This is a multicenter, open label extension study. Subjects who have completed treatment in the parent study of pertuzumab, either alone or with a combination agent, and who received at least one dose of pertuzumab in the parent study are eligible for inclusion in this trial if they are continuing to receive clinical benefit.
Interventions
DRUGPertuzumab
Pertuzumab was supplied as a single-use liquid formulation.
Sponsors
Genentech, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Signed informed consent * ECOG performance status of 0, 1, or 2 * Completion of treatment in a previous Genentech sponsored, Phase II cancer study with pertuzumab, either alone or with a combination agent, in which at least one dose of pertuzumab was received in the parent study * Less than 3 months since last dose of pertuzumab on the parent study * Use of an effective means of contraception for men or for women of childbearing potential * Granulocyte count \>= 1500/uL * Platelet count \>= 75,000/uL * Hemoglobin \>= 9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbepoetin \[Aranesp(R)\] is permitted) * Serum bilirubin less than or equal to the upper limit of normal (ULN) (unless due to Gilbert's disease) * Alkaline phosphatase, AST, and ALT \<= 2.5x ULN (\<= 5x ULN for subjects with liver metastases; no alkaline phosphatase upper limit for subjects with bone metastases) * Serum creatinine \<= 1.5x ULN * International normalized ratio (INR) \< 1.5 and activated partial thromboplastin time (aPTT) \< 1.5x ULN (except for subjects receiving warfarin)
Exclusion criteria
* Recent (within the last 3 months), current, or planned participation in a experimental drug study other than a Genentech-sponsored pertuzumab cancer study * Any unresolved or irreversible NCI-CTC Grade 3 or 4 adverse event or clinically meaningful cardiac adverse event (any grade) that is pertuzumab-related and ongoing from the parent study * Recent (within the last 3 months) or current treatment with HER pathway inhibitors other than pertuzumab (e.g., Herceptin(R) \[Trastuzumab\], Iressa\<TM\> \[gefitinib\], Tarceva\<TM\> \[erlotinib hydrochloride\], C225, CI1033, or TAK165) or other monoclonal antibodies * Clinical evidence of central nervous system or brain metastases * Ejection fraction ≤50%, as determined by ECHO (or MUGA) * Uncontrolled hypercalcemia (\> 11.5 mg/dL) * Recent anthracycline exposure (within the last 3 months) or cumulative exposure of \> 360 mg/m\^2 doxorubicin or equivalent (i.e., liposomal doxorubicin, \> 120 mg/m\^2 mitoxantrone, or \> 90 mg/m\^2 idarubicin) * Ongoing corticosteroid use (except for subjects who are on stable doses of \< 20 mg of prednisone daily \[or equivalent\] or who are taking corticosteroids for reasons other than cancer) * Other malignancies (except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, or basal or squamous cell skin cancer) * Serious systemic disease, including active infection, uncontrolled hypertension (diastolic blood pressure \> 100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia \[i.e., atrial fibrillation\], paroxysmal supraventricular tachycardia, or controlled hypertension are eligible) * Liver disease (including viral or other hepatitis), current alcohol abuse, or cirrhosis * Known human immunodeficiency virus infection * Pregnancy or lactation * Major surgery or significant traumatic injury within 3 weeks prior to Day 1 * Inability to comply with study and follow-up procedures * Any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the continued use of an investigational drug or that may render the subject at high risk from treatment complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants Who Experienced an Adverse Event | Baseline to the end of the study (up to 2 years, 5 months) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) | Baseline to the end of the study (up to 2 years, 5 months) | A best overall response could occur at any time during the study and was determined by Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions (TL) or the disappearance of all non-TLs and normalization of tumor marker level. A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started for TLs and the persistence of 1 or more non-TL(s) and/or the maintenance of tumor marker level above normal limits. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started or the appearance of one or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Pertuzumab Participants received the same dose of pertuzumab that they received in their parent Phase II trial, either 420 mg or 1050 mg, intravenously on Day 1 of every 3 week cycle until disease progression.
Pertuzumab: Pertuzumab was supplied as a single-use liquid formulation. | 3 |
| Total | 3 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | disease progression | 3 |
Baseline characteristics
| Characteristic | Pertuzumab |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 1 / 3 |
| serious Total, serious adverse events | 0 / 3 |
Outcome results
Primary
Percentage of Participants Who Experienced an Adverse Event
Time frame: Baseline to the end of the study (up to 2 years, 5 months)
Population: Safety population: Participants who received at least 1 dose of pertuzumab. Percentage of participants
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab | Percentage of Participants Who Experienced an Adverse Event | 33.3 percentage of participants |
Secondary
Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)
A best overall response could occur at any time during the study and was determined by Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions (TL) or the disappearance of all non-TLs and normalization of tumor marker level. A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started for TLs and the persistence of 1 or more non-TL(s) and/or the maintenance of tumor marker level above normal limits. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started or the appearance of one or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.
Time frame: Baseline to the end of the study (up to 2 years, 5 months)
Population: Safety population: Participants who received at least 1 dose of pertuzumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pertuzumab | Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) | Complete response | 0.0 percentage of participants |
| Pertuzumab | Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) | Partial response | 0.0 percentage of participants |
| Pertuzumab | Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) | Stable disease | 33.3 percentage of participants |
| Pertuzumab | Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) | Progressive disease | 33.3 percentage of participants |
| Pertuzumab | Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) | Unknown | 33.3 percentage of participants |